INNOVATE CorpVATE
VATE
About: Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
Employees: 3,161
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
73% more capital invested
Capital invested by funds: $11.8M [Q4 2024] → $20.3M (+$8.54M) [Q1 2025]
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 29 [Q4 2024] → 32 (+3) [Q1 2025]
1.84% more ownership
Funds ownership: 17.96% [Q4 2024] → 19.8% (+1.84%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for VATE.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5.5 million, or $1.42 per share, on June 16, 2025 to DBMG's stockholders of record at the close of business on June 2, 2025. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $5 million of the total $5.5 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.
Neutral
GlobeNewsWire
1 month ago
DBM Global Enters Into an Amended and Restated Credit Agreement
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit agreement that provides for an $85 million term loan and a $135 million revolving credit facility (the “Credit Facility”), which will be used to fully repay DBMG's existing debt obligations and provide additional working capital capacity.
Neutral
Seeking Alpha
2 months ago
INNOVATE Corp. (VATE) Q1 2025 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Conference Call Participants Operator Good afternoon. And welcome to INNOVATE's First Quarter 2025 Earnings Conference Call.
Neutral
GlobeNewsWire
2 months ago
INNOVATE Corp. Announces First Quarter 2025 Results
- Infrastructure: DBM Global first quarter revenue of $264.9 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function - - Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year -
Neutral
GlobeNewsWire
2 months ago
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.
Neutral
Seeking Alpha
3 months ago
INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Neel Sikka - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Conference Call Participants Brian Charles - R.W. Pressprich Operator Good afternoon and welcome to INNOVATE Corp's Fourth Quarter and Full Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
3 months ago
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 -
Neutral
GlobeNewsWire
4 months ago
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2024 on Monday, March 31, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.
Neutral
GlobeNewsWire
4 months ago
MediBeacon® Transdermal GFR System receives device approval in China
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February published MediBeacon study results on measured GFR (mGFR) using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages.
Neutral
GlobeNewsWire
5 months ago
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.
Charts implemented using Lightweight Charts™